Bristol Myers reports promising preliminary results for its next-gen CAR T therapy CC-97540, showing safety and early efficacy in a Phase 1 study for severe autoimmune diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback